Jay Flatley
Advisor at Time BioVentures
About
Jay Flatley led Illumina as CEO from 1999 to 2016, later serving as Executive Chairman and then Chairman of the Board, and oversaw the company's move into next-generation sequencing including its 2006 acquisition of Solexa. Earlier he co-founded and led Molecular Dynamics to its 1993 IPO and held roles at Plexus Computers, Manning Technologies, and Spectra Physics. He holds a B.A. in economics from Claremont McKenna College and B.S. and M.S. degrees in industrial engineering from Stanford University.
Invests in
Biotech
Investments
Board seats
CoherentDenaliIridia
As listed on the firm's website.
Colleagues at Time BioVentures
Bradford Cornell
Advisor at Time BioVentures
D.A. Wallach
General Partner at Time BioVentures
DA Wallach
General Partner at Time BioVentures
Daniel L. Vasella, M.D.
Advisor at Time BioVentures
Jack Schoenfeld
Analyst at Time BioVentures
Jim Allison, Ph.D.
Scientific Advisor at Time BioVentures
Leonard Schaeffer
Advisor at Time BioVentures
Pam Sharma, M.D., Ph.D.
Scientific Advisor at Time BioVentures